Literature DB >> 12430892

The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases.

Chin-Yang Li1.   

Abstract

Chronic myeloprolifeative diseases (CMPD) are clonal hematopoietic stem cell disorders characterized by excessive proliferation and production of one or more of the myeloid cells and are subclassified according to the predominant cells, such as chronic myelogenous leukemia (CNL), chronic eosinophilic leukemia (CEL), polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (CIMF). This brief review focuses on the characteristic morphology of each clinical entity and the useful cytochemical (including leukocyte alkaline phosphatase, myeloperoxidase, butyrate esterase, chloroacetate esterase and cyanide-resistant peroxidase) and immunohistochemical (including von Willebrand factor/CD61, keratin, tryptase, CD117, CD68 (PGM-1), c-Mpl and bFGF) stains for differential diagnosis.

Entities:  

Mesh：

Year:  2002        PMID： 12430892     DOI： 10.1007/bf03165077

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  9 in total

Review 1.  Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry.

Authors:  C Y Li
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

2.  Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow.

Authors:  S Y Yoon; A Tefferi; C Y Li
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

3.  Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.

Authors:  R A Mesa; C Y Li; G Schroeder; A Tefferi
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 4.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

5.  Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.

Authors:  S Y Yoon; A Tefferi; C Y Li
Journal:  Haematologica       Date:  2001-01       Impact factor: 9.941

6.  Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders.

Authors:  S Y Yoon; C Y Li; R V Lloyd; A Tefferi
Journal:  Int J Hematol       Date:  2000-10       Impact factor: 2.490

7.  Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis.

Authors:  A Tefferi; S Y Yoon; C Y Li
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates.

Authors:  S Y Yoon; C Y Li; A Tefferi
Journal:  Eur J Haematol       Date:  2000-09       Impact factor: 2.997

9.  von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders.

Authors:  S S Chuang; Y C Jung; C Y Li; Y C Yung
Journal:  Am J Clin Pathol       Date:  2000-04       Impact factor: 2.493
  9 in total
  2 in total

1.  Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.

Authors:  Oliver Bock; Guntram Büsche; Christina Koop; Sabine Schröter; Thomas Buhr; Hans Kreipe
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

2.  A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.

Authors:  Kai B Kaufmann; Albert Gründer; Tobias Hadlich; Julius Wehrle; Monika Gothwal; Ruzhica Bogeska; Thalia S Seeger; Sarah Kayser; Kien-Binh Pham; Jonas S Jutzi; Lucas Ganzenmüller; Doris Steinemann; Brigitte Schlegelberger; Julia M Wagner; Manfred Jung; Britta Will; Ulrich Steidl; Konrad Aumann; Martin Werner; Thomas Günther; Roland Schüle; Alessandro Rambaldi; Heike L Pahl
Journal:  J Exp Med       Date:  2012-01-09       Impact factor: 14.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.